

| Adverse Event | amlodipine | | Placebo | |
|---------------|-----------------|----------------|----------------|----------------|
| | M=% (N=1218) | F=% (N=512) | M=% (N=914) | F=% (N=336) |
| Edema | 5.6 | 14.6 | 1.4 | 5.1 |
| Flushing | 1.5 | 4.5 | 0.3 | 0.9 |
| Palpitations | 1.4 | 3.3 | 0.9 | 0.9 |
| Somnolence | 1.3 | 1.6 | 0.8 | 0.3 |

The following events occurred in $\leq 1\%$ but $>0.1\%$ of patients treated with amlodipine in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship: **Cardiovascular:** arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, hypotension, peripheral ischemia, syncope, tachycardia, postural dizziness, postural hypotension, vasculitis. **Central and Peripheral Nervous System:** hyposthesia, neuropathy peripheral, paresthesia, tremor, vertigo. **Gastrointestinal:** anorexia, constipation, dyspepsia, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia. **General:** allergic reaction, asthenia, back pain, hot flushes, malaise, pain, rigors, weight gain, weight decrease. **Musculoskeletal System:** arthralgia, arthrosis, muscle cramps, myalgia. **Psychiatric:** sexual dysfunction (male and female), insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalization. **Respiratory System:** dyspnea, epistaxis. **Skin and Appendages:** angioedema, erythema multiforme, pruritus, rash, rash erythematous, rash maculopapular. **Special Senses:** abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus. **Urinary System:** micturition frequency, micturition disorder, nocturia. **Autonomic Nervous System:** dry mouth, sweating increased. **Metabolic and Nutritional:** hyperglycemia, thirst. **Hemopoietic:** leukopenia, purpura, thrombocytopenia. The following events occurred in $\leq 0.1\%$ of patients treated with amlodipine in controlled clinical trials or under conditions of open trials or marketing experience: cardiac failure, pulse irregularity, extrasystoles, skin discoloration, urticaria, skin dryness, alopecia, dermatitis, muscle weakness, twitching, ataxia, hypertension, migraine, cold and clammy skin, apathy, agitation, amnesia, gastritis, increased appetite, loose stools, coughing, rhinitis, dysuria, polyuria, parosmia, taste perversion, abnormal visual accommodation, and xerophthalmia. Other reactions occurred sporadically and cannot be distinguished from medications or concurrent disease states such as myocardial infarction and angina. Amlodipine therapy has not been associated with clinically significant changes in routine laboratory tests. No clinically relevant changes were noted in serum potassium, serum glucose, total triglycerides, total cholesterol, HDL cholesterol, uric acid, blood urea nitrogen, or creatinine. The following postmarketing event has been reported infrequently with amlodipine treatment where a causal relationship is uncertain: gynecomastia. In postmarketing experience, jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis) in some cases severe enough to require hospitalization have been reported in association with use of amlodipine. Amlodipine has been used safely in patients with chronic obstructive pulmonary disease, well-compensated congestive heart failure, peripheral vascular disease, diabetes mellitus, and abnormal lipid profiles. **The Atorvastatin Component of CADUET:** Atorvastatin is generally well-tolerated. Adverse reactions have usually been mild and transient. In controlled clinical studies of 2502 patients, $<2\%$ of patients were discontinued due to adverse experiences attributable to atorvastatin calcium. The most frequent adverse events thought to be related to atorvastatin calcium were constipation, flatulence, dyspepsia, and abdominal pain. **Clinical Adverse Experiences:** Adverse experiences reported in $\geq 2\%$ of patients in placebo-controlled clinical studies of atorvastatin, regardless of causality assessment, are shown in Table 3.

Table 3. Adverse Events in Placebo-Controlled Studies (% of Patients)

| Body System/ Adverse Event | atorvastatin | | | | |
|-------------------------------|------------------|----------------|---------------|---------------|---------------|
| | Placebo N=270 | 10 mg N=863 | 20 mg N=36 | 40 mg N=79 | 80 mg N=94 |
| BODY AS A WHOLE | | | | | |
| Infection | 10.0 | 10.3 | 2.8 | 10.1 | 7.4 |
| Headache | 7.0 | 5.4 | 16.7 | 2.5 | 6.4 |
| Accidental Injury | 3.7 | 4.2 | 0.0 | 1.3 | 3.2 |
| Flu Syndrome | 1.9 | 2.2 | 0.0 | 2.5 | 3.2 |
| Abdominal Pain | 0.7 | 2.8 | 0.0 | 3.8 | 2.1 |
| Back Pain | 3.0 | 2.8 | 0.0 | 3.8 | 1.1 |
| Allergic Reaction | 2.6 | 0.9 | 2.8 | 1.3 | 0.0 |
| Asthenia | 1.9 | 2.2 | 0.0 | 3.8 | 0.0 |
| DIGESTIVE SYSTEM | | | | | |
| Constipation | 1.8 | 2.1 | 0.0 | 2.5 | 1.1 |
| Diarrhea | 1.5 | 2.7 | 0.0 | 3.8 | 5.3 |
| Dyspepsia | 4.1 | 2.3 | 2.8 | 1.3 | 2.1 |
| Flatulence | 3.3 | 2.1 | 2.8 | 1.3 | 1.1 |
| RESPIRATORY SYSTEM | | | | | |
| Sinusitis | 2.6 | 2.8 | 0.0 | 2.5 | 6.4 |
| Pharyngitis | 1.5 | 2.5 | 0.0 | 1.3 | 2.1 |
| SKIN AND APPENDAGES | | | | | |
| Rash | 0.7 | 3.9 | 2.8 | 3.8 | 1.1 |
| MUSCULOSKELETAL SYSTEM | | | | | |
| Arthralgia | 1.5 | 2.0 | 0.0 | 5.1 | 0.0 |
| Myalgia | 1.1 | 3.2 | 5.6 | 1.3 | 0.0 |

Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): In ASCOT involving 10,305 participants treated with atorvastatin 10 mg daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with atorvastatin was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up. The following adverse events were reported, regardless of causality assessment, in patients treated with atorvastatin in clinical trials. The events in italics occurred in $\geq 2\%$ of patients and the events in plain type occurred in $<2\%$ of patients. **Body as a Whole:** Chest pain, face edema, fever, neck rigidity, malaise, photosensitivity reaction, generalized edema. **Digestive System:** Nausea, gastroenteritis, liver function tests abnormal, colitis, vomiting, gastritis, dry mouth, rectal hemorrhage, esophagitis, eructation, glossitis, mouth ulceration, anorexia, increased appetite, stomatitis, biliary pain, cheilitis, duodenal ulcer, dysphagia, enteritis, melena, gum hemorrhage, stomach ulcer, tenesmus, ulcerative stomatitis, hepatitis, pancreatitis, cholestatic jaundice. **Respiratory System:** Bronchitis, rhinitis, pneumonia, dyspnea, asthma, epistaxis. **Nervous System:** Insomnia, dizziness, paresthesia, somnolence, amnesia, abnormal dreams, libido decreased, emotional lability, incoordination, peripheral neuropathy, torticollis, facial paralysis, hyperkinesia, depression, hyposthesia, hypertension. **Musculoskeletal System:** Arthritis, leg cramps, bursitis, tenosynovitis, myasthenia, tendinous contracture, myositis. **Skin and Appendages:** Pruritus, contact dermatitis, alopecia, dry skin, sweating, acne, urticaria, eczema, seborrhea, skin ulcer. **Urogenital System:** Urinary tract infection, urinary frequency, cystitis, hematuria, impotence, dysuria, kidney calculus, nocturia, epididymitis, fibrocystic breast, vaginal hemorrhage, albuminuria, breast enlargement, metrorrhagia, nephritis, urinary incontinence, urinary retention, urinary urgency, abnormal ejaculation, uterine hemorrhage. **Special Senses:** Amblyopia, tinnitus, dry eyes, refraction disorder, eye hemorrhage, deafness, glaucoma, parosmia, taste loss, taste perversion. **Cardiovascular System:** Palpitation, vasodilatation, syncope, migraine, postural hypotension, phlebitis, arrhythmia, angina pectoris, hypertension. **Metabolic and Nutritional Disorders:** Peripheral edema, hyperglycemia, creatine phosphokinase increased, gout, weight gain, hypoglycemia. **Hemic and Lymphatic System:** Eosinophilia, anemia, lymphadenopathy, thrombocytopenia, petechia. **Postintroduction Reports with Atorvastatin:** Adverse events associated with atorvastatin therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following: angioedema, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), and rhabdomyolysis. **Pediatric Patients (ages 10-17 years):** In a 26-week controlled study in boys and postmenarchal girls (n=140), the safety and tolerability profile of atorvastatin 10 to 20 mg daily was generally similar to that of placebo (see PRECAUTIONS, Pediatric Use).

OVERDOSAGE: There is no information on overdosage with CADUET in humans. **Information on Amlodipine:** Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg and 100 mg amlodipine/kg in mice and rats, respectively, caused deaths. Single oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg in dogs (11 or more times the maximum recommended clinical dose on a mg/m² basis) caused a marked peripheral vasodilation and hypotension. Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly a reflex tachycardia. In humans, experience with intentional overdosage of amlodipine is limited. Reports of intentional overdosage include a patient who ingested 250 mg and was asymptomatic and was not hospitalized; another (120 mg) was hospitalized, underwent gastric lavage and remained normotensive; the third (105 mg) was hospitalized and had hypotension (90/50 mmHg) which normalized following plasma expansion. A patient who took 70 mg amlodipine and an unknown quantity of benzodiazepine in a suicide attempt developed shock which was refractory to treatment and died the following day with abnormally high benzodiazepine plasma concentration. A case of accidental drug overdose has been documented in a 19-month-old male who ingested 30 mg amlodipine (about 2 mg/kg). During the emergency room presentation, vital signs were stable with no evidence of hypotension, but a heart rate of 180 bpm. Ipecac was administered 3.5 hours after ingestion and on subsequent observation (overnight) no sequelae were noted. If massive overdose should occur, active cardiac and respiratory monitoring should be instituted. Frequent blood pressure measurements are essential. Should hypotension occur, cardiovascular support including elevation of the extremities and the judicious administration of fluids should be initiated. If hypotension remains unresponsive to these conservative measures, administration of vasopressors (such as phenylephrine) should be considered with attention to circulating volume and urine output. Intravenous calcium gluconate may help to reverse the effects of calcium entry blockade. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit. **Information on Atorvastatin:** There is no specific treatment for atorvastatin overdosage. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.

*Based on patient weight of 50 kg.

**These events occurred in less than 1% in placebo-controlled trials, but the incidence of these side effects was between 1% and 2% in all multiple dose studies.

Rx only

Manufactured by:
Pfizer Ireland Pharmaceuticals
Dublin, Ireland

© 2004 Pfizer Ireland Pharmaceuticals

Distributed by:



Pfizer Labs

Division of Pfizer Inc., NY, NY 10017

Rev. 1 October 2004



Learning Curve Evident in Carotid Stent Complications

BY MITCHEL L. ZOLER
Philadelphia Bureau

PHILADELPHIA — Minimizing the complications from carotid artery stenting may require accumulating experience with up to 200 patients, according to the records at a single medical center in Italy.

An analysis of the correlates of death or major stroke in a series of more than 600 patients treated with carotid artery stenting at the University of Perugia during 2001-2006 showed that the only strongly significant link was with the time when the stenting was done, Dr. Piergiorgio Cao said at the Vascular Annual Meeting.

Patients who were among the first 195 treated with carotid stenting in Perugia, during 2001-2003, had an average incidence of perioperative death or major stroke of about 3%, compared with a 1% rate among the next 432 patients who were treated in 2004-2006, a statistically significant difference, said Dr. Cao, a vascular surgeon at the University of Perugia.

In some major trials of carotid artery stenting, operators are required to have performed at least 30 stenting procedures as a criterion for participating, noted Dr. Robert Hobson, chief of vascular surgery at the

University of Medicine and Dentistry of New Jersey in Newark. But Dr. Cao hesitated to recommend an alternative, minimum number based on his findings.

"The prior suggested number [of 30 cases] seems too low to ensure the safety of carotid artery stenting," said Dr. Cao. But "our results do not equal guidelines." He did recommend that operators start by performing carotid stenting in "low-risk patients with easy-access vessels."

Another facet of the analysis looked at the time during carotid stenting when complications occurred. To run this analysis, the Perugia researchers divided the carotid stenting procedure into five phases: Phase 1 was initial catheterization of the carotid artery, phase 2 was crossing the stenosis, phase 3 was deployment of the protective device and the stent, phase 4 was the first 24 hours following the procedure, and phase 5 was the period beyond the first 24 hours through 30 days of follow-up.

Of the 10 patients who had major strokes in the full series, 4 had strokes during phase 1 and 6 had strokes during phase 3. But there were no strokes during phase 1 among patients treated during 2004-2006. "That can be strictly related to the learning curve effect," Dr. Cao said. ■

Stents Raise PSV Threshold For Detecting Carotid Stenosis

BY MITCHEL L. ZOLER
Philadelphia Bureau

PHILADELPHIA — The current standards for diagnosing carotid artery stenosis by ultrasound velocity are too low once a stent is placed in the vessel, according to the results of a study of 80 patients presented at the Vascular Annual Meeting.

The standard ultrasound threshold for diagnosing carotid stenosis of 50% or more is a peak systolic velocity (PSV) of at least 125 cm/s. But after a carotid artery is stented, its biomechanical properties change and the PSV rises.

In stented patients, the flag for carotid stenosis of 50% or more should be a PSV of at least 217 cm/s, Dr. Sam A. Zakhary said at the meeting, which was sponsored by the Society for Vascular Surgery.

Another marker of stenosis is the ratio of the PSV in the internal carotid artery to that in the common carotid artery (ICA/CCA).

The standard threshold for flagging stenosis of 50% or more is a ratio of at least 2.0, but in the study, the best threshold was found to be a ratio of at least 2.98, said Dr. Zakhary, a vascular surgeon at Baylor University Medical Center in Dallas.

In the 80-patient series, carotid angiography was done within 30 days of stenting, and ultrasounds were taken within 30 days of angiography. The 28 patients with less than 50% carotid stenosis after stenting were followed for 6 years, during which 5 developed stenosis of 50% or more.

Of the 80 patients, 40 were misdiagnosed with a residual carotid stenosis of 50% or more after stenting because their PSV was at least 125 cm/s. But none had this high a level of carotid stenosis when assessed with carotid angiography.

In contrast, a PSV of at least 217 cm/s showed high sensitivity and specificity for diagnosing 50% or more stenosis in the 80 patients (see box), Dr. Zakhary said. ■

Suggested Ultrasound Criteria for Diagnosing $\geq 50\%$ Stenosis in Stented Carotid Arteries

| Measure | Sensitivity | Specificity |
|---|-------------|-------------|
| Peak systolic velocity (PSV) ≥ 217 cm/s | 100% | 95% |
| Internal carotid artery/common carotid artery PSV ratio ≥ 2.98 | 83% | 100% |

Note: Based on a study of 80 patients.
Source: Dr. Zakhary